Although the latter yeast studies partially overlap with ours, supporting the functional role of USP22 in promoting the OXPHOS activity, our work reveals for the first time the pronounced therapeutic value of USP22 to combat certain OXPHOS-driven CSC-associated aggressive properties and improving response to standard therapies in HER2+-BC and BLBC. This evidence concerns the gene USP22 and breast cancer.